share_log

RBC Capital Reiterates Outperform on Biogen, Maintains $340 Price Target

Benzinga ·  Jun 2, 2023 10:46

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $340 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment